{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:55:02Z","timestamp":1787230502363,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40272-023-00586-7","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T17:02:20Z","timestamp":1690909340000},"page":"499-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.1007","volume":"25","author":[{"given":"Shengbo","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9775-0865","authenticated-orcid":false,"given":"Libo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"10","key":"586_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2036.2011.04857.x","volume":"34","author":"C Jakobsen","year":"2011","unstructured":"Jakobsen C, Bartek J Jr, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease\u2014a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217\u201324.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"586_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","volume":"33","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment Pharmacol Ther. 2011;33(9):987\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"586_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"586_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","volume":"21","author":"K Papamichael","year":"2015","unstructured":"Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182\u201397.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"586_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","volume":"61","author":"S Danese","year":"2012","unstructured":"Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918\u201332.","journal-title":"Gut"},{"issue":"13","key":"586_CR6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"586_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135(4):1130\u201341.","journal-title":"Gastroenterology"},{"issue":"20","key":"586_CR8","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"key":"586_CR9","unstructured":"https:\/\/www.drugs.com\/newdrugs\/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html"},{"key":"586_CR10","unstructured":"https:\/\/www.drugs.com\/newdrugs\/janssen-announces-fda-approval-stelara-ustekinumab-adults-moderately-severely-active-ulcerative-5084.html"},{"issue":"1","key":"586_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"586_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"key":"586_CR13","first-page":"2","volume":"2","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohn\u2019s Colitis. 2020;2:2.","journal-title":"J Crohn's Colitis."},{"issue":"1","key":"586_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/gutjnl-2018-317987","volume":"69","author":"D Turner","year":"2020","unstructured":"Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, et al. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020;69(1):32\u201341.","journal-title":"Gut"},{"issue":"7","key":"586_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"key":"586_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jclinepi.2015.07.010","volume":"69","author":"B Guo","year":"2016","unstructured":"Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol. 2016;69:199-207.e2.","journal-title":"J Clin Epidemiol"},{"key":"586_CR17","unstructured":"Moga C, Guo B, Schopflocher D, Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics, (2012)."},{"issue":"5","key":"586_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ecco-jcc\/jjy206","volume":"13","author":"M Chavannes","year":"2019","unstructured":"Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S, et al. Management of paediatric patients with medically refractory crohn\u2019s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578\u201384.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"586_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","volume":"69","author":"JR Dayan","year":"2019","unstructured":"Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"586_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jgh.15128","volume":"36","author":"I Takeuchi","year":"2021","unstructured":"Takeuchi I, Arai K, Kyodo R, Sato T, Tokita K, Hirano Y, et al. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children\u2019s hospital in Japan. J Gastroenterol Hepatol. 2021;36(1):125\u201330.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"586_CR21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.16388","volume":"53","author":"J Dhaliwal","year":"2021","unstructured":"Dhaliwal J, McKay HE, Deslandres C, Debruyn J, Wine E, Wu A, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther. 2021;53(12):1300\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"586_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","volume":"27","author":"MT Dolinger","year":"2021","unstructured":"Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(8):1210\u20134.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"586_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MPG.0000000000003230","volume":"73","author":"FS Kim","year":"2021","unstructured":"Kim FS, Patel PV, Stekol E, Ali S, Hamandi H, Heyman MB, et al. Experience using ustekinumab in pediatric patients with medically refractory crohn disease. J Pediatr Gastroenterol Nutr. 2021;73(5):610\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"586_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.12688\/f1000research.22673.1","volume":"9","author":"P Do","year":"2020","unstructured":"Do P, Andersen J, Patel A, Semrin G, Sifuentes-Dominguez L, Luu P, et al. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn\u2019s disease: a retrospective chart review. F1000Research. 2020;9:316.","journal-title":"F1000Research."},{"issue":"2","key":"586_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5217\/ir.2019.09164","volume":"19","author":"A Cohen","year":"2021","unstructured":"Cohen A, Ahmed N, Sant\u2019Anna A. Ustekinumab for the treatment of refractory pediatric Crohn\u2019s disease: a single-center experience. Intestinal Res. 2021;19(2):217\u201324.","journal-title":"Intestinal Res"},{"issue":"11","key":"586_CR26","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","volume":"15","author":"JR Rosh","year":"2021","unstructured":"Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ, et al. Ustekinumab in paediatric patients with moderately to severely active crohn\u2019s disease: pharmacokinetics, safety, and efficacy results from unistar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931\u201342.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"586_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/MPG.0000000000003608","volume":"75","author":"A Yerushalmy-Feler","year":"2022","unstructured":"Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, Kolho KL, Levine A, Olbj\u00f8rn C, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric crohn disease (the Speed-up Study): a multicenter study from the pediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717\u201323.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"586_CR28","first-page":"2","volume":"2","author":"M Koudsi","year":"2023","unstructured":"Koudsi M, Martinez-Vinson C, Pigneur B, Willot S, Djamal D, Enaud R, et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023;2:2.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"586_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ibd\/izab015","volume":"28","author":"F Bermejo","year":"2022","unstructured":"Bermejo F, Jim\u00e9nez L, Algaba A, Vela M, Bastida G, Merino O, et al. Re-induction with intravenous ustekinumab in patients with crohn\u2019s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"586_CR30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","volume":"52","author":"M Iborra","year":"2020","unstructured":"Iborra M, Beltr\u00e1n B, Fern\u00e1ndez-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"586_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10620-022-07501-z","volume":"68","author":"A Forss","year":"2023","unstructured":"Forss A, Clements M, Myrelid P, Strid H, S\u00f6derman C, Wagner A, et al. Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of life in crohn\u2019s disease. Dig Dis Sci. 2023;68(1):65\u201376.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"586_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ecco-jcc\/jjac108","volume":"17","author":"D Casas-Deza","year":"2023","unstructured":"Casas-Deza D, Lamuela-Calvo LJ, Gomoll\u00f3n F, Arbon\u00e9s-Mainar JM, Caballol B, Gisbert JP, et al. Effectiveness and safety of ustekinumab in elderly patients with crohn\u2019s disease: real world evidence from the ENEIDA registry. J Crohns Colitis. 2023;17(1):83\u201391.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"586_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/apt.17386","volume":"57","author":"C Taxonera","year":"2023","unstructured":"Taxonera C, Olivares D, L\u00f3pez-Garc\u00eda ON, Alba C. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR34","doi-asserted-by":"crossref","unstructured":"Rub\u00edn de C\u00e9lix C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of crohn's disease: systematic review and meta-analysis of observational studies. J Clin Med. 2022;11:14","DOI":"10.3390\/jcm11144202"},{"issue":"7","key":"586_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/apt.16802","volume":"55","author":"H Yang","year":"2022","unstructured":"Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55(7):764\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"586_CR36","doi-asserted-by":"crossref","unstructured":"Casas Deza D, Garc\u00eda L\u00f3pez S, Lafuente Blasco M, Vicente Lid\u00f3n R, Ner\u00edn de la Puerta J, Pe\u00f1a Gonzalez E, et al. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. Gastroenterologia y hepatologia. 2020;43(3):126-32.","DOI":"10.1016\/j.gastre.2019.09.010"},{"issue":"1","key":"586_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","volume":"22","author":"RS Parra","year":"2022","unstructured":"Parra RS, Chebli JMF, Queiroz NSF, Dami\u00e3o A, de Azevedo MFC, Chebli LA, et al. Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn\u2019s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22(1):199.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"586_CR38","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/apt.14016","volume":"45","author":"C Ma","year":"2017","unstructured":"Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"586_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","volume":"23","author":"C Ma","year":"2017","unstructured":"Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe crohn\u2019s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"586_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm8122140","volume":"8","author":"A Kubesch","year":"2019","unstructured":"Kubesch A, Rueter L, Farrag K, Krause T, Stienecker K, Hausmann J, et al. Short and Long-term effectiveness of ustekinumab in patients with crohn\u2019s disease: real-world data from a German IBD cohort. J Clin Med. 2019;8:12.","journal-title":"J Clin Med"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00586-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T08:01:48Z","timestamp":1702886508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00586-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"17 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data used during the study are available from the corresponding author by request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of date and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SF and SZ performed screening of papers, data extraction, quality assessment, collected and analyzed the data. SF and CZ wrote and revised the manuscript. SF performed the literature search. LW developed the study concept and protocol, held the leading role in coordinating the project, senior authorship to resolve disagreements on inclusion, exclusion and quality assessment of papers, and critiqued and edited the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}